Aberdeen Group’s Relay Therapeutics RLAY Stock Holding History

Aberdeen Group’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-101,111	Closed	-$4.62M	–	1030
2021 Q1	$4.62M	Buy	+101,111	New	+$4.39M	0.01%	660

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aberdeen Group's RLAY Position: Q2 2021 in Review

Aberdeen Group sold out of Relay Therapeutics (RLAY) in Q2 2021, closing a stake of 101,111 shares — an estimated $4.62M sold.

Aberdeen Group first reported a position in RLAY in Q1 2021 and held it in 1 quarter. The position peaked at $4.62M in Q1 2021. 125 funds tracked by Wall St. Rank hold RLAY as of Q2 2021.

Aberdeen Group reported no remaining Relay Therapeutics position as of Q2 2021 after selling out during the quarter.
Aberdeen Group sold 101,111 Relay Therapeutics shares in Q2 2021, an estimated $4.62M.
Aberdeen Group first reported a position in Relay Therapeutics in Q1 2021 and held it in 1 quarter.
Aberdeen Group's Relay Therapeutics position peaked at $4.62M in Q1 2021.
125 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2021.

Based on Aberdeen Group's 13F filing for Q2 2021, filed 10 Aug 2021.